Wegovy Phase 3 Meets Goal in Children Under 12
Novo Nordisk announced that its STEP Young phase 3 trial of once-weekly Wegovy met its primary endpoint in children aged 6 to under 12 with obesity.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Novo Nordisk released the first results from STEP Young on September 7. The multinational, randomized, double-blind phase 3 trial enrolled 165 children aged 6 to under 12 with obesity and evaluated once-weekly semaglutide alongside a reduced-calorie diet and increased physical activity.
The company said the trial met its primary endpoint and reduced body mass index. At week 68, 40.4% of the treatment group had moved outside the obesity classification, compared with no participants in the placebo group.
What the trial found
Novo Nordisk evaluated semaglutide, the active ingredient in Wegovy, in children aged 6 to under 12 with obesity. Both groups participated in reduced-calorie eating and increased physical activity as part of the study design.
The primary-endpoint result and the week-68 comparison indicate an effect on BMI and obesity classification within this trial population. These findings concern a defined study group and do not mean every child will have the same response.
Limits and clinical context
Wegovy is currently authorized for obesity treatment in adolescents aged 12 and older. A successful trial in younger children is distinct from a regulatory decision to expand the authorized age range.
The reports did not detail specific side effects or recovery considerations. A qualified physician should assess individual variation, the child's health, and the role of diet and activity before a family makes treatment decisions.
Questions for a consultation
Families can ask how a clinician determines obesity classification for a child and whether the STEP Young population resembles the child's circumstances. They can also discuss how reduced-calorie eating and increased activity would fit into an overall plan.
Parents should consult a qualified physician about the current age authorization, expected monitoring, possible side effects, recovery considerations, and individual variation. The published figures should be interpreted as trial-group results rather than a prediction for one child.
Frequently asked questions
Is Wegovy approved for children under 12?
Wegovy is currently authorized for obesity treatment from age 12. The STEP Young result is a phase 3 trial finding in children aged 6 to under 12, not an authorization expanding use to that age group.
What did the Wegovy trial find in younger children?
Novo Nordisk said the trial met its primary endpoint and lowered BMI. At week 68, 40.4% of the treatment group had moved outside the obesity classification, while no participant in the placebo group had done so.
Did the trial include diet and exercise changes?
Yes. The trial evaluated once-weekly semaglutide together with a reduced-calorie diet and increased physical activity in 165 children aged 6 to under 12 with obesity.
Questions to take to a clinician
- How is obesity classification assessed for my child's age?
- Is Wegovy currently authorized for a child under 12?
- How do diet and physical activity fit into the treatment plan?
- What side effects and monitoring should our family discuss?
- How could individual variation affect interpretation of the trial results?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
